China approves Eli Lilly's GLP-1 weight loss pill.

Updated 2026-11-13 · told from many outlets at once

China has approved Eli Lilly's oral GLP-1 weight loss drug, Muyouda. This is the first time Chinese regulators have authorized an oral version of this medication. Previously, only injectable GLP-1 medications were approved for weight management.

Eli Lilly became the first pharmaceutical company authorized by China for an oral GLP-1 weight loss drug.
China’s National Health Commission stated the proportion of overweight or obese people could reach more than 65 percent by 2030.
Yang Huang of JP Morgan forecasted annual sales of GLP-1 therapies in China could reach 30 billion yuan in the next five to seven years.

Open the full story — timeline, facts and every outlet

Outlets: ABC Color, BusinessLIVE, China Labour Bulletin, Citizen Digital, El Economista (México), Free Malaysia Today, Le Temps, ORF News (Austria), Observador, RTP Notícias

Written by AI from the outlets' reporting and checked automatically; it can contain mistakes. How Daily Brief works · Privacy